CA4 and neoplasm: Recently, Li et al. [64] have come up with a multi-drug delivery system (DDS) based on mesoporous silica nanoparticles (MSNs) exploiting the strategy discovered by Sengupta et al. Li et al. Have demonstrated co-loading of antiangiogenic CA4 and chemotherapeutic Dox in the MSNs followed by anchoring the MSNs onto the iRGD peptide that has been reported to be the ligand with high affinity for α2β3 receptor overexpressed by a number of tumor cells as well as endothelial cells.